logo
episode-header-image
Dec 2024
28m 6s

The Sunday Read: ‘Ozempic Could Crush th...

The New York Times
About this episode
For decades, Big Food has been marketing products to people who can’t seem to stop eating, and now, suddenly, they can. The active ingredient in new drugs like Ozempic, Wegovy and Zepbound mimics a natural hormone that slows digestion and signals fullness to the brain. Around seven million Americans take these drugs, but estimates from Morgan Stanley sugges ... Show More
Up next
Today
Natalie Harp’s Devotion to Trump
Natalie Harp is a constant presence at President Trump’s side. She’s a 35-year-old gatekeeper, deciding much of what he sees. She stays up late with him to draft his social media posts and even texts with world leaders on his behalf. Today, Maggie Haberman, a White House correspo ... Show More
22m 49s
Yesterday
Think Baseball Is Boring? The Savannah Bananas Are Here to Fix That.
Jesse and Emily Cole created theSavannah Bananaswith a simple mission in mind: to make baseball as entertaining as possible. They introduced some innovations to America’s pastime, including twerking umpires, stilt-walking pitchers and TikTok-ready choreographed dance numbers. The ... Show More
36m 52s
Aug 22
An Expert on Conflict Says Your Relationships Are Doomed Without It
The author Priya Parker says the key to human connection is to lean into the fight. Thoughts? Email us at theinterview@nytimes.com Watch our show on YouTube: youtube.com/@TheInterviewPodcast For transcripts and more, visit: nytimes.com/theinterview Subscribe today at nytimes.com/ ... Show More
42m 13s
Recommended Episodes
Jul 2023
How Drugs Like Ozempic Are Changing What We Think About Weight Loss
You may have heard about Ozempic, Wegovy and Mounjaro. It’s tough to miss the online chatter, the ads on TV and all the news coverage. They are part of a class of drugs originally designed to treat diabetes, and all three have been shown to help people lose significant amounts of ... Show More
28m 5s
Jul 2023
One Thing: Weight Loss Drugs: Trend or Treatment?
A new group of drugs for type 2 diabetes and obesity have shown to be more effective for weight loss than any previous medications. Some medications like Ozempic and Wegovy have surged in popularity thanks in part to celebrity use. But who should be taking them? And are they safe ... Show More
17m 14s
Dec 2024
Deep Dive: The Gold Rush to Cure the Obesity Epidemic
<p>GLP-1 weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound, are credited with reversing obesity trends in the U.S. for the first time in decades, according to a new study in the Journal of the American Medical Association. The episode highlights the rapid ... Show More
8m 47s
Oct 2023
Semaglutide: Decoding the hype around the weight loss wonder drug
<p>From Elon Musk to several Hollywood celebrities, the weight loss wonder drug, semaglutide, is taking the world by storm. What was an unintended consequence of a diabetes control med, the emergence of significant weight loss has raised the expectation of the wonder drug becomin ... Show More
32m 7s
Jun 2024
The weight-loss drug revolution
Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ... Show More
17m 28s
Sep 2023
After Ozempic
Ozempic and other drugs like it are being heralded as game changers for weight loss. Radio Atlantic host Hanna Rosin talks to Atlantic staff writer Olga Khazan about what it means that this medical intervention has arrived at a time when our society seems to be easing away from f ... Show More
24m 15s
Dec 2024
How Ozempic Transformed the Way We Look at Obesity
Ozempic, Wegovy, and Mounjaro, are being called “miracle drugs” with users boasting about their fast results. Dr. Sanjay Gupta takes a deep dive into how they disrupted the entire weight loss industry and changed the conversation about obesity.  Learn more about your ad choices. ... Show More
23m 47s